Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border

Chansuda Wongsrichanalai, Steven R Meshnick, Chansuda Wongsrichanalai, Steven R Meshnick

Abstract

Resistance to many antimalaria drugs developed on the Cambodia-Thailand border long before developing elsewhere. Because antimalaria resistance is now a global problem, artemisinin-based combination therapies (ACTs) are the first-line therapies in most malaria-endemic countries. However, recent clinical and molecular studies suggest the emergence of ACT-resistant Plasmodium falciparum infections in the Cambodia-Thailand border area, where standard ACT is artesunate and mefloquine. These ACT failures might be caused by high-level mefloquine resistance because mefloquine was used for monotherapy long before the introduction of ACT. This observation raises 2 questions. First, how can existing P. falciparum-resistant strains be controlled? Second, how can the evolution of new ACT- resistant strains be avoided elsewhere, e.g., in Africa? Enforcement of rational drug use and improved diagnostic capacity are among the measures needed to avoid and contain ACT resistance.

Figures

Figure
Figure
Map of the Cambodia–Thailand border showing the town of Pailin, Cambodia, and the provinces of Chanthaburi and Trat, Thailand; the areas are collectively known as the epicenter of drug-resistant malaria.

References

    1. World Health Organization. Guidelines for the treatment of malaria. WHO/HTM/MAL 2006.1108 [cited 2008 Mar 5]. Geneva: The Organization; 2006. Available from
    1. World Health Organization. Containment of malaria multi-drug resistance on the Cambodia-Thailand border. Report of an informal consultation, Phnom Penh, 29–30 January 2007. Report no. SEA-MAL-246 [cited 2008 Mar 5]. Available from
    1. Wongsrichanalai C, Prajakwong S, Meshnick SR, Shanks GD, Thimasarn K. Mefloquine—its 20 years in the Thai Malaria Control Program. Southeast Asian J Trop Med Public Health. 2004;35:300–8.
    1. Thimasarn K, Sirichaisinthop J, Chanyakhun P, Palananth C, Rooney W. A comparative study of artesunate and artemether in combination with mefloquine on multidrug resistant falciparum malaria in eastern Thailand. Southeast Asian J Trop Med Public Health. 1997;28:465–71.
    1. Denis MB, Tsuyuoka R, Poravuth Y, Narann TS, Seila S, Lim C, et al. Surveillance of the efficacy of artesunate and mefloquine combination for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Health. 2006;11:1360–6. 10.1111/j.1365-3156.2006.01690.x
    1. Vijaykadga S, Rojanawatsirivej C, Cholpol S, Phoungmanee D, Nakavej A, Wongsrichanalai C. In vivo sensitivity monitoring of mefloquine monotherapy and artesunate-mefloquine combinations for the treatment of uncomplicated falciparum malaria in Thailand in 2003. Trop Med Int Health. 2006;11:211–9. 10.1111/j.1365-3156.2005.01557.x
    1. Snounou G, Beck HP. The use of PCR genotyping in the assessment of recrudescence or reinfection after antimalarial drug treatment. Parasitol Today. 1998;14:462–7. 10.1016/S0169-4758(98)01340-4
    1. Cowman MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature. 2000;403:906–9. 10.1038/35002615
    1. Alker AP, Lim P, Sem R, Shah NK, Yi P, Bouth DM, et al. pfmdr1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian–Thai border. Am J Trop Med Hyg. 2007;76:641–7.
    1. Nelson AL, Purfield A, McDaniel P, Uthaimongkol N, Buathong N, Sriwichai S, et al. pfmdr1 genotyping and in vivo mefloquine resistance on the Thai-Myanmar border. Am J Trop Med Hyg. 2005;72:586–92.
    1. Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L, et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet. 2004;364:438–47. 10.1016/S0140-6736(04)16767-6
    1. Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B, et al. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet. 2005;366:1960–3. 10.1016/S0140-6736(05)67787-2
    1. Sidhu AB, Uhlemann AC, Valderramos SG, Valderramos JC, Krishna S, Fidock DA. Decreasing pfmdr1 copy number in Plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J Infect Dis. 2006;194:528–35. 10.1086/507115
    1. Duong S, Chanthap L, Babu VVRS. Piloting of a strategy for collection of malaria information from the private sector, Cambodia, Final Report, March 2005. National Centre for Parasitology, Entomology and Malaria Control GTZ BACKUP Initiative. Phnom Penh: The Initiative; 2005
    1. Hastings IM, Ward SA. Coartem (artemether-lumefantrine) in Africa: the beginning of the end? J Infect Dis. 2005;192:1303–4. 10.1086/432554
    1. Rathod PK, McErlean T, Lee PC. Variations in frequencies of drug resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A. 1997;94:9389–93. 10.1073/pnas.94.17.9389
    1. Sem R, Lim P, Muth S, Kim S, Chim P, Duong S, et al. Efficacy of current standard therapy for uncomplicated P. falciparum and P. vivax malaria in central Cambodia. Abstracts of the Joint International Tropical Medicine Meeting 2007. “Health Security in the Tropics"; 2007 Nov 29–30; Bangkok. Abstract No. 47.
    1. Wongsrichanalai C, Thimasarn K, Sirichaisinthop J. Antimalarial drug combination policy: a caveat. Lancet. 2000;355:2245–7. 10.1016/S0140-6736(00)02416-8
    1. Bloland PB, Ettling M, Meek S. Combination therapy for malaria in Africa: hype or hope? Bull World Health Organ. 2000;78:1378–88.
    1. World Health Organization. Resistance to artemisinin derivatives along the Thai-Cambodian border. Wkly Epidemiol Rec. 2007;82:360.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다